Theratechnologies (TH.TO) on Wednesday said it swung to a first-quarter profit as revenue surged 17%.

The company recorded a net profit of US$117,000, or nil per share, compared with a loss of US$4.5 million or US$0.10 per share, in the prior year period.

Sales rose to US$19 million, boosted by a 45% jump in Egrifta SV sales. The increase was mostly due to higher unit sales and a higher selling price. Trogarzo sales fell 22% to US$5.2 million, due to an 18% drop in unit sales.

"We are extremely pleased to have ended our fiscal first quarter in a strong position with total revenue of $19 million, representing 17% growth year-over-year, a net profit of $117,000, and positive adjusted EBITDA of $2.3 million. While this number is mainly related to reloading the pipeline following an end to the temporary supply disruption, the fundamentals of the business and specifically demand for EGRIFTA SV remains very strong," said Paul Levesque, chief executive officer. "Our HIV portfolio led by the EGRIFTA franchise will continue to remain our engine of growth for years with the recent approval of EGRIFTA WR which will drive further adoption and adherence."